Cochrane · systematic review · CD008209
Hormone therapy for uterine and endometrial development in women with premature ovarian insufficiency
Craciunas, L, Zdoukopoulos, N, Vinayagam, S, et al. · Cochrane Database of Systematic Reviews · 2022 · Cochrane Library
Gynaecology and FertilityAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
21
current version
GRADE rated
8
No studies
13
Included studies
NR
No studies 13 · 61.9%Ungraded 0 · 0%Very low 8 · 38.1%Low 0 · 0%Moderate 0 · 0%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Conjugated oral oestrogens compared to transdermal 17ß‐estradiol in girls with Turner syndrome
Population: girls with Turner syndrome who were treated with prepubertal growth hormone
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Uterine volume (mL)(measured after 12 months) Conjugated oral oestrogens vs transdermal 17ß‐estradiol | no estimate extracted | 1 study · 12 participants | Very low Downgraded: risk of bias, imprecision |
Endometrial thickness Conjugated oral oestrogens vs transdermal 17ß‐estradiol | no estimate extracted | NR | No studies |
Endometrial histology Conjugated oral oestrogens vs transdermal 17ß‐estradiol | no estimate extracted | NR | No studies |
Uterine perfusion Conjugated oral oestrogens vs transdermal 17ß‐estradiol | no estimate extracted | NR | No studies |
Reproductive outcomes Conjugated oral oestrogens vs transdermal 17ß‐estradiol | no estimate extracted | NR | No studies |
Adverse events Conjugated oral oestrogens vs transdermal 17ß‐estradiol | no estimate extracted | NR | No studies |
Low versus high 17ß‐oestradiol dose in women with Turner syndrome
Population: young women with Turner syndrome who have completed pubertal induction
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Uterine volume (mL)(measured after 3 years) Low vs high 17ß‐oestradiol dose | no estimate extracted | 1 study · 20 participants | Very low Downgraded: risk of bias, imprecision |
Uterine volume (mL) (measured after 5 years) Low vs high 17ß‐oestradiol dose | no estimate extracted | 1 study · 20 participants | Very low Downgraded: risk of bias, imprecision |
Endometrial thickness Low vs high 17ß‐oestradiol dose | no estimate extracted | NR | No studies |
Endometrial histology Low vs high 17ß‐oestradiol dose | no estimate extracted | NR | No studies |
Uterine perfusion Low vs high 17ß‐oestradiol dose | no estimate extracted | NR | No studies |
Reproductive outcomes Low vs high 17ß‐oestradiol dose | no estimate extracted | NR | No studies |
Adverse events Low vs high 17ß‐oestradiol dose | no estimate extracted | 1 study · 20 participants | Very low Downgraded: risk of bias, imprecision |
Oral versus vaginal administration of oestradiol and dydrogesterone in women diagnosed with premature ovarian insufficiency
Population: women with premature ovarian insufficiency (POI) awaiting oocyte donation
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Uterine volume (mL)(measured after 14 days) Oral vs vaginal administration of oestradiol and dydrogesterone | no estimate extracted | 1 study · 20 participants | Very low Downgraded: risk of bias, imprecision |
Uterine volume (mL)(measured after 21 days) Oral vs vaginal administration of oestradiol and dydrogesterone | no estimate extracted | 1 study · 20 participants | Very low Downgraded: risk of bias, imprecision |
Endometrial thickness (mm)(measured after 14 days) Oral vs vaginal administration of oestradiol and dydrogesterone | no estimate extracted | 1 study · 20 participants | Very low Downgraded: risk of bias, imprecision |
Endometrial thickness (mm)(measured after 21 days) Oral vs vaginal administration of oestradiol and dydrogesterone | no estimate extracted | 1 study · 20 participants | Very low Downgraded: risk of bias, imprecision |
Endometrial histology Oral vs vaginal administration of oestradiol and dydrogesterone | no estimate extracted | NR | No studies |
Uterine perfusion Oral vs vaginal administration of oestradiol and dydrogesterone | no estimate extracted | NR | No studies |
Reproductive outcomes Oral vs vaginal administration of oestradiol and dydrogesterone | no estimate extracted | NR | No studies |
Adverse events Oral vs vaginal administration of oestradiol and dydrogesterone | no estimate extracted | NR | No studies |